Overall verdict
Neutral
6.4/10
1-year performance
+20.61%
Score breakdown
Up 20.6% over 1 year, 98% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 2.8/10.
16 analysts, target +0.1% vs the price.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers ; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers ;
SYLVANT for the treatment of adult patients with multicentric castleman disease ; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer ; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor ; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK ;
BG-60366, an EGFR-targeted CDAC ; BG-89894 (SYH2039), a MAT2A Inhibitor ; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor ; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody ; BGB-26808, a HPK-1 Inhibitor ; BGB-C354, an anti-B7H3 ADC ; Zanidatamab, a bispecific HER2-targeted antibody ; BG-C137, an anti-FGFR2b ADC ; BGB-53038, a Pan-KRAS Inhibitor ; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody ;
BGB-B3227, an anti-MUC1xCD16A bispecific antibody ; BG-C477, an anti-CEAADC ; BGB-43395, a CDK4 Inhibitor ; BG-68501, a CDK2 Inhibitor ; BG-C9074, an anti-B7H4 ADC ; BGB-21447, a Bcl-2 Inhibitor ; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
Switzerland
CEO
John Oyler
Founded
2010
Employees
12 000
Revenue / employee
446 430 USD
Next earnings
March 25, 2027 (estimated)
Institutional holders
- FMR LLC2.07%
- GEODE CAPITAL MANAGEMENT, LLC0.03%
- Rest of the register97.90%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
424.73 USD
52-week low
253.95 USD
1-year performance
20.61%
Rising
Year-to-date performance
37.76%
Rising
Drawdown
-0.97%
Near its high
Position in the 52-week range
98% of range
Against the world ETF
Over 11 years, from February 2016 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned more, but shaking 3.9 times harder: for the risk taken, the ETF paid better.
$10,000 placed at the end of February 2016 are worth today
| BeOne Medicines | $126,423 |
| World ETF | $36,827 |
| S&P 500 | $46,427 |
| Risk-free placement | $12,813 |
The risk
- Shaking:the share moves 3.9 times as much as the world ETF.
- Worst fall:-70Â % between September 2021 and May 2022. $10,000 placed at the top fell to $3,004. The world ETF, at worst: -34Â %. The share has not returned to its high yet.
BeOne Medicines earned 3 times as much as the world ETF since 2016
Value of $10,000 placed at the end of February 2016, dividends reinvested, in dollars
- BeOne Medicines: $126,423
- World ETF: $36,827
- S&P 500: $46,427
- Risk-free placement: $12,813
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 385.00 USD - 538.52 USD (2 methods agree)
The price implies growth of 11.32% per year; the company grows at 25.00%.
Gross margin 87.4%, net margin 13.9%, ROIC 14.5%, ROE 18.5%.
Net margin
13.86%
Fair
Sector -14.06%|S&P 13.40%
Gross margin
87.40%
Fair
Return on equity (ROE)
18.45%
Fair
Sector -18.81%|S&P 17.06%
Return on invested capital (ROIC)
14.51%
Fair
Free cash flow margin (FCF)
21.93%
High
Profit-to-cash conversion (FCF conversion)
1.58x
Exceptional
Margin stability
3298.3 pts
Very uneven
Revenue to net income
Growth
10.0/10Revenue up 34.0% over 1 year, 76.9% a year over 5.
Revenue (trailing 12 months)
6.6Md USD
Revenue growth (1y)
33.99%
Hyper-growth
Revenue growth (3y)
278.80%
Hyper-growth
EPS growth (1y)
201.24%
Hyper-growth
EPS CAGR (5y)
—
EPS revisions (3 months)
31.08%
Sharply revised up
Valuation
4.4/10P/E 53.3x, forward P/E 46.8x, EV/EBITDA 31.0x, PEG 0.04. The multiple sits in the 100th percentile of its own 5-year history.
P/E (TTM)
53.3x
Expensive
Sector 29.6x|S&P 23.6x
Forward P/E
46.8x
Very expensive
EV / EBITDA
31.0x
Expensive
Sector 17.2x|S&P 15.5x
PEG
0.04
Growth unpriced
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
436.43 USD
Fairly priced
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
47.1Md USD
Financial strength
9.4/10Cash covers 283.5% of the debt, net debt/EBITDA -4.4x.
Net debt / EBITDA
-4.4x
Net cash
Gearing (net debt / equity)
-65.00%
Net cash
Cash
5.8Md USD
Cash / market cap
12.40%
Solid
Cash / total debt
283.53%
Net cash
Interest coverage
9.3x
Solid
Net debt
-3.8Md USD
Equity
5.8Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 424.00 USD
- MM20378.88
- MM50365.80
- MM200326.72
- RSI 1472.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.62%
200-day average slope, 3 months
+3.73%
50-day average slope, 1 month
+2.40%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.66 % per day
Volatility change
+40.67%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 8.98 (16) | 9.83 (10) | 6 895 (32) | 1 442 (16) | 1 012 (27) |
| 2027 | 10.77 (16) | 10.80 (16) | 7 934 (32) | 1 820 (19) | 1 284 (27) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | ONC | 6.4 | 6.5 | 47.1Md USD | 53.3x | 13.9 % | 34.0 % | 14.5 % | -4.4x | 3.1 % | 20.6 % | ||
| 3 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 6 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
